SuperworthNurix Therapeutics EPS NRIX
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Aug 31, 2026
- $2.31
- Latest quarter, Q3 FY26
- $4.73
- Fiscal year 2025
- −$3.04
Nurix Therapeutics' earnings per share was $2.31 over the twelve months to Aug 31, 2026.
In its latest quarter, Q3 FY26, it was $4.73.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.04 | n/a |
| FY2024 | −$2.89 | n/a |
| FY2023 | −$2.65 | n/a |
| FY2022 | −$3.73 | n/a |
| FY2021 | −$2.73 | n/a |
| FY2020 | −$5.10 | n/a |
| FY2019 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $4.73 | n/a | $2.31 | |
| Q2 FY26 | −$0.81 | n/a | −$3.45 | |
| Q1 FY26 | −$0.79 | n/a | −$3.16 | |
| Q4 FY25 | −$0.82 | n/a | −$3.04 | |
| Q3 FY25 | −$1.03 | n/a | −$2.97 | |
| Q2 FY25 | −$0.52 | n/a | −$2.61 | |
| Q1 FY25 | −$0.67 | n/a | −$2.80 | |
| Q4 FY24 | −$0.75 | n/a | −$2.89 | |
| Q3 FY24 | −$0.67 | n/a | −$2.91 | |
| Q2 FY24 | −$0.71 | n/a | −$2.92 | |
| Q1 FY24 | −$0.76 | n/a | −$2.66 | |
| Q4 FY23 | −$0.77 | n/a | −$2.65 |
Against its peers
Companies in Drug Manufacturers - General nearest Nurix Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NRIXNurix Therapeutics | $2.31 | |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| OGNOrganon | $0.77 | −71% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| LQDALiquidia | $1.39 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| Peer median | $2.61 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Nurix Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.